These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11018093)

  • 1. Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines.
    Mandler R; Wu C; Sausville EA; Roettinger AJ; Newman DJ; Ho DK; King CR; Yang D; Lippman ME; Landolfi NF; Dadachova E; Brechbiel MW; Waldmann TA
    J Natl Cancer Inst; 2000 Oct; 92(19):1573-81. PubMed ID: 11018093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugates.
    Mandler R; Kobayashi H; Davis MY; Waldmann TA; Brechbiel MW
    Bioconjug Chem; 2002; 13(4):786-91. PubMed ID: 12121134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity.
    Mandler R; Kobayashi H; Hinson ER; Brechbiel MW; Waldmann TA
    Cancer Res; 2004 Feb; 64(4):1460-7. PubMed ID: 14973048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of antiproliferative activity of a geldanamycin-Herceptin immunoconjugate.
    Mandler R; Dadachova E; Brechbiel JK; Waldmann TA; Brechbiel MW
    Bioorg Med Chem Lett; 2000 May; 10(10):1025-8. PubMed ID: 10843208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of an antibody to target geldanamycin.
    Mendelsohn J
    J Natl Cancer Inst; 2000 Oct; 92(19):1549-51. PubMed ID: 11018081
    [No Abstract]   [Full Text] [Related]  

  • 6. Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells.
    Wang K; Ma Q; Ren Y; He J; Zhang Y; Zhang Y; Chen W
    Oncol Rep; 2007 Jan; 17(1):89-96. PubMed ID: 17143483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.
    Basso AD; Solit DB; Munster PN; Rosen N
    Oncogene; 2002 Feb; 21(8):1159-66. PubMed ID: 11850835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
    Larbouret C; Robert B; Navarro-Teulon I; Thèzenas S; Ladjemi MZ; Morisseau S; Campigna E; Bibeau F; Mach JP; Pèlegrin A; Azria D
    Clin Cancer Res; 2007 Jun; 13(11):3356-62. PubMed ID: 17545543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates.
    Savellano MD; Pogue BW; Hoopes PJ; Vitetta ES; Paulsen KD
    Cancer Res; 2005 Jul; 65(14):6371-9. PubMed ID: 16024640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.
    Münster PN; Marchion DC; Basso AD; Rosen N
    Cancer Res; 2002 Jun; 62(11):3132-7. PubMed ID: 12036925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest.
    Bedin M; Gaben AM; Saucier C; Mester J
    Int J Cancer; 2004 May; 109(5):643-52. PubMed ID: 14999769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition.
    Coyne CP; Ross MK; Bailey JG
    J Drug Target; 2009 Jul; 17(6):474-89. PubMed ID: 19480561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases.
    Zheng FF; Kuduk SD; Chiosis G; Münster PN; Sepp-Lorenzino L; Danishefsky SJ; Rosen N
    Cancer Res; 2000 Apr; 60(8):2090-4. PubMed ID: 10786665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Geldanamycin inhibits proliferation and motility of human HER2/neu-overexpressing breast cancer cell line SKBr3].
    Wang K; Ma QY; Ren Y; He JJ; Chen WK
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct; 27(10):1480-4. PubMed ID: 17959518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
    Schulte TW; Neckers LM
    Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Free and N-(2-hydroxypropyl)methacrylamide copolymer-bound geldanamycin derivative induce different stress responses in A2780 human ovarian carcinoma cells.
    Nishiyama N; Nori A; Malugin A; Kasuya Y; Kopecková P; Kopecek J
    Cancer Res; 2003 Nov; 63(22):7876-82. PubMed ID: 14633716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity.
    An WG; Schnur RC; Neckers L; Blagosklonny MV
    Cancer Chemother Pharmacol; 1997; 40(1):60-4. PubMed ID: 9137531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells.
    Tahmasebi F; Kazemi T; Amiri MM; Khoshnoodi J; Mahmoudian J; Bayat AA; Jeddi-Tehrani M; Rabbani H; Shokri F
    Immunotherapy; 2014; 6(1):43-9. PubMed ID: 24341883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.